

Realinvest.dk A/S

Vesterbro 1F, DK-5000 Odense C, Denmark

Tel.: (+45) 66 13 72 77

Fax: (+45) 66 17 72 59

www.realinvest.dk

Copenhagen Stock Exchange

Nicolai Plads 6

DK-1007 Copenhagen K

Att. Office for Issuer Relations (Udstederrelationer)

Odense, January 9, 2004

For general release

Realinvest.dk A/S has today acquired the total share capital of AntibodyShop A/S (Central Company Register (CVR) no. 18645882) for a total of DKK 35,500,000 from Immunolex Holding ApS. The purchasing price is covered by the issue of 11,093,750 new B shares in Realinvest.dk A/S, of nominal value DKK 3.00 per share, at an issue price of DKK 3.20 per share, corresponding to an increase in the nominal B-share capital of DKK 33,281,250, in an issue directed to Immunolex Holding ApS. AntibodyShop A/S will henceforth be a subsidiary company of Realinvest.dk A/S, in which Realinvest.dk A/S has 100% ownership.

AntibodyShop A/S is a biotechnological company with innovative research into and product development of new analyses relevant to the diagnosis of disease.

It has further been decided, in addition to the above-mentioned share issue, to issue a new subscription of B shares in Realinvest.dk A/S in another directed issue at the price of DKK 3.20 per share without subscription rights for existing shareholders, to yield a minimum of DKK 5,000,000 and a maximum of DKK 25,000,000 in cash, corresponding to an increase in the nominal B-share capital of between DKK 4,687,500 and DKK 23,437,500.

It will also be proposed at the next general meeting of shareholders to increase the B-share capital by nominally DKK 10,799,738 by converting debt totaling DKK 11,519,720 at a rate of DKK 3.20 per B share of nominal value DKK 3.00, corresponding to the issue of 3,599,912 new B shares.

The overall increase in the nominal B-share capital will hereafter amount to a minimum of DKK 48,768,488 and a maximum of DKK 67,518,488.

The Board of Directors has today also appointed new management for Realinvest.dk A/S.

Finally, the Board of Directors has decided to call an extraordinary general meeting of shareholders on January 23, 2004.

In connection with the above, a shareholders' prospectus will be drawn up as soon as possible. Application will be made to the Copenhagen Stock Exchange for listing of the overall increase in the B-share capital after the publication of the prospectus.

In its annual report for 2002/3, Realinvest.dk A/S stated:

"By winding up unwanted activities, the Company has prepared itself for almost any future that the Board of Directors may choose. Among these possibilities, fusion with an existing company that thereby wishes to be listed on the Stock Exchange is probably the most obvious. The Board of Directors is authorized to issue new shares for a total of 500 million DKK in this eventuality."

In seeking new activities the Board of Directors of Realinvest.dk A/S has decided to acquire a biotechnological company that focuses on the development of new analyses relevant to human diagnosis. The Board of Directors has entered into a contract to purchase the total share capital of AntibodyShop A/S. AntibodyShop A/S will henceforth be a 100%-owned subsidiary company of Realinvest.dk A/S.

History

AntibodyShop A/S was originally set up in close collaboration with the Department of Immunological Research and Development at the State Serum Institute (Statens Serum Institut) through the purchase of exclusive sales and development rights to many of the Institute's monoclonal antibodies. These exploitation rights were supported by development and production agreements. This starting point has given the Company a significant strength in certain diagnostic and research areas with a primary focus on infectious diseases and immunology.

From this point of departure AntibodyShop A/S has generated turnover since the financial year 2001.

Until June 30, 2003, AntibodyShop A/S was physically located at Statens Serum Institut. As a natural consequence of the positive development and expansion of its own research and development programs, as well as the creation of additional academic and industrial alliances, its activities were moved to rented premises with newly installed laboratories in Gentofte on July 1, 2003.

Business area

AntibodyShop A/S focuses on research and development of new diagnostic methods with special emphasis on critically ill patients, comprising new analyses for a series of selected diagnostic and monitoring parameters, including monitoring the effects of the often very expensive newly developed therapeutic agents that have recently been or shortly will be introduced for treating these patients. Product development is based on considerable clinical experience in combination with newly developed technologies for which patent applications have been submitted.

AntibodyShop A/S's extensive research and development activities are at various stages in different programs. A series of analytical kits have completed development, including kits for determining mannan-binding lectin (MBL; on sale), surfactant protein D (SP-D) and properdin. These analyses are relevant for determining susceptibility for infectious diseases. The most active new development programs concern measuring blood concentrations of a series of proteins and peptides that indicate the state of critically ill patients' defense systems in infections and multiple injuries. In this connection a kit for the rapid analysis of free and actin-bound Gc-globulin has been developed for determining the capacity to resist organ damage, and further analyses for the rapid diagnosis of Gram-negative infection, activation of protein C and activation of coagulation and fibrinolytic processes are under active development. The first tests will be marketed for clinical use in 2004 after the completion of satisfactory clinical validation.

An important concept for the profile of diagnostic tests is a technological development program aimed at the rapidly growing POC (point-of-care) diagnostic market. Under this program a POC-diagnostic platform is being developed for new diagnostic analyses applicable to intensive care, whether in general intensive care, surgical or coronary units, and in certain cases to general practitioners.

POC tests can be divided into two categories:

- Diagnostic analyses for hospital use
- Diagnostic analyses for use in the general practitioner's surgery or for home testing

POC products vary from medium-sized test systems used in hospitals and requiring readings from an instrument in a ward side-room, to single-use tests that can be used by the general practitioners or in the patient's home.

AntibodyShop A/S is primarily focusing on the hospital market in its new program for diagnostic analyses for critically ill patients. The following general criteria and test requirements apply to these POC tests:

- The analyses should be rapid, i.e. that the result should be available within a few minutes to at most two hours. The fully developed POC tests must be robust and accurate and must be possible to perform by doctors and nurses without the assistance of the central hospital laboratory.
- New tests should be developed that have not previously been available in a format permitting near-patient testing (bedside tests), either completely new tests or tests that can replace existing costly, laborious and slow procedures, which produce the test result at such a late stage in the course of illness that it is no longer relevant for clinical decision-making, and
- Relevant analyses in the POC test program should as far as possible be compatible with existing analytical technology already available to hospitals.

The strategy for the POC platform is to develop specific new diagnostic POC tests with a short time of analysis from sample collection from the critically ill patient to obtaining the final result. In this way the special indications for the use of new and often expensive new therapeutic agents can be identified with certainty, and therapy can subsequently be monitored and adjusted to the individual patient's actual needs, with a significant saving of costs and evident advantages to the patient in the form of better treatment outcome.

Organization

The innovative research and development of new diagnostic analytical methods in AntibodyShop A/S is carried out by its in-house scientific staff whose activities are supported and coordinated by senior research staff. There is a very close collaboration with academic and other alliance partners and scientific advisors. The alliance partners and advisors differ from those of many other biotechnology companies in that they collaborate actively with specific research and development contracts. The Company's overall scientific expertise and experience comprise the scientific areas central to the development of diagnostic tests: immunology, antibody development, immunochemical analysis, molecular biology, protein chemistry, infectious diseases, intensive care, endocrinology and pharmacology.

Several alliances and collaborative projects have been established in the areas of research, development and test validation. The most important are those with the Department of Immunology and Microbiology at the University of Southern Denmark at Odense, the Intensive Care Unit at the National Hospital (Rigshospitalet) in Copenhagen, and a collaboration with the Paul Ehrlich Institute in Germany. Development and production of specific antibodies are also being carried out under special development contracts with research institutions in Spain.

Company strategy is to maintain an organizational flexibility to focus on the innovative aspects of the development process, together with validation and quality assurance. The collective scientific expertise and experience within AntibodyShop A/S enables the time from the first idea for a new diagnostic test to its complete development and subsequent marketing in validated form to be relatively short.

AntibodyShop A/S out-sources its routine tasks and the continuing production of finished products.

Sales and sales channels

AntibodyShop A/S maintains a fully integrated e-commerce platform, www.antibodyshop.com, through which it is selling an extensive list of diagnostic and research products. The platform uses e-commerce tools for prioritizing future development tasks by analyzing specific searches and inquiries. The intention is to make www.antibodyshop.com customers' preferred channel for repeat orders.

Currently, AntibodyShop A/S has an active customer portfolio of more than 100 institutional customers. The customer profile consists of approximately 33% biotechnology companies, 22% universities, 22% university hospitals and medical schools, 13% other hospitals, and 10% governmental research institutions. Customers are distributed among 34 different countries in all parts of the world.

Among these customers are prestigious private institutions such as the Mayo Clinic, leading universities and medical schools in the USA (Harvard, Yale, Washington University St. Louis, Johns Hopkins and Duke University), the UK (Cambridge, University College London, Imperial College London) and Canada (McGill), as well as important governmental research centers such as the Pasteur Institute in Paris.

At present, AntibodyShop A/S has distributors in USA, China, Japan, Australia, Austria and Holland, and negotiations are in progress with potential distributors in the UK and Belgium. Initially only non-exclusive distributor agreements are made, to preserve the Company's freedom to develop its own sales and to enter into other or supplementary alliances. The aim is to increase the number of distributors in the next 12 to 24 months and thus obtain a broad representation on the relevant world market.

The diagnostic market

AntibodyShop A/S operates in the so-called IVD (in vitro diagnostic) market, which is the largest single sector of the medical technology industry and which is further subdivided into several different areas. The IVD world market was estimated as \$21 billion for the year 2000 and is expected to grow to \$26,6 billion in 2005 (Freedonia, 2001; Reuters 2002; Kalorama 2002). Growth is expected to continue for the next 5-10 years, and different sources estimate an annual growth of 6-9%. Clinical and immunochemical market segments together make up almost two-thirds of the total IVD market, immunochemistry alone accounting for about 25%, estimated as \$5,65-7,23 billion in 2000.

The primary markets for IVD are Europe, USA and Japan, which together account for 85% of total world sales (Kalorama 2002; Reuters 2002). The European IVD reagent market amounted to €4,2 billion in 2001 (European Diagnostic Manufacturers' Association). Within the IVD market, monoclonal antibodies is one of the fastest growing segments and sales for the year 2002 were estimated at \$3 billion in the USA alone, with a possibility of worldwide sales reaching \$8 billion in 2004 (D&MD report 2001).

Within the overall IVD market, the market for POC diagnostic tests has shown very high annual growth rates in the USA and Germany, closely followed by the rest of Europe and Japan. The highest growth rate, estimated at about 20% per annum, has been seen in tests for heart and circulatory disorders. Regions of the world at an intermediate stage of development (e.g. South-East Asia) also make up a large part of the market. The growth drivers are the availability of new technology platforms and the demand by both patients and physicians for more effective diagnosis and treatment. AntibodyShop A/S seeks to respond to these market forces, both when prioritizing development programs and when marketing the new products.

Risk profile

AntibodyShop A/S's business area is characterized by a high degree of complexity and rapid technological change, together with an intense and constantly changing competition for the market. This is due to the large number of innovative companies in the field. These market players compete with various aspects of the Company's specific research and development areas in a number of ways, including the risk that relevant parts of the development may be covered by other companies' immaterial rights in the form of patents, or that other companies may bring directly competing

products more rapidly to market than AntibodyShop A/S. The pace of development is therefore decisive.

In contrast with the development of therapeutic products, the development of diagnostic applications is characterized by a relatively modest expenditure of time and money, just as the success rate for obtaining the necessary marketing approvals for the products is higher.

The Company's future success also depends on its ability to attract and retain competent staff, to obtain patent protection of its technologies and new product applications, and to maintain security with respect to its know-how and trade secrets.

AntibodyShop A/S's management is of the opinion that the Company possesses technologies and know-how that in combination with its rapid development policy constitute important and relevant competitive elements within its field.

Historical financial data for AntibodyShop A/S

<u>Result</u>					<u>Balance</u>				
(DKK 1000)	Audited 2000	Audited 2001	Audited 2002	Unaudited 31.12.03	(DKK 1000)	Audited 2000	Audited 2001	Audited 2002	Unaudited 31.12.03
Revenues	0	2,198	4,095	6,382	Immaterial fixed assets	6,396	11,089	8,039	10,955
Gross income	0	1,608	2,981	4,548	Inventoriable material	107	535	494	865
%	0	73%	73%	71%	Biological assets	0	15,808	17,404	19,000
Biological assets	0	0	1,596	1,596	Material fixed assets	107	16,343	17,898	19,865
Operating expenses	0	(2,081)	(6,241)	(3,335)	Total assets	6,596	28,563	27,341	33,040
Result of operations	0	(473)	(1,664)	2,809	Share capital	213	213	3,500^{*)}	3,500^{*)}
Depreciation	(894)	(1,278)	(1,887)	(1,009)	Equity	(2,872)	5,818	4,516	5,124
Result before interest	(894)	(1,751)	(3,551)	1,800	Deferred tax	0	4,742	5,221	5,700
					Interest-bearing loans	9,468	18,003	17,604	22,215
					Total liability	6,596	28,563	27,341	33,040

*) The share capital consists of 3,500,000 shares of nominal value DKK 1.00 each. All shares carry the same rights

The Annual Report for AntibodyShop A/S is prepared in accordance with requirements of the new Danish law on annual accounts for class-B companies. The accounting year for AntibodyShop A/S coincides with the calendar year.

Historical ownership and management

Immunolex Holding ApS owns the total share capital of AntibodyShop A/S.

Immunolex Holding ApS is owned by CRE ApS with 46% of the capital, DKA-Consult ApS with 46% of the capital, Thea Olesen with 6% of the capital and CJ IT Management ApS with 2% of the capital

The entire capital of CRE ApS is owned by Christian F. Rovsing.

The entire capital of DKA-Consult ApS is owned by Lasse Lindblad.

The entire capital of CJ IT Management ApS is owned by Claus Jepsen.

The Chairman of the Board of Directors of Immunolex Holding ApS is Christian F. Rovsing (1936), civil engineer (1961), member of the European Parliament since 1989, member of the Board of Directors of Rovsing A/S, Rovsing Dynamics A/S, the European Parliament Voluntary Pension Fund,

Luxembourg, and Chairman of the Board of Directors of Immunolex Therapeutics ApS and Rovsing Management A/S.

The other members of the Board of Directors are: Claus Jepsen (1940), M.Sc., MBA, founder and/or managing director of IT companies; Thea Olesen (1966), lawyer; and Lasse Lindblad (1964), M.Sc., manager and/or managing director of financial or commercial companies.

The Chairman of the Board of Directors of AntibodyShop A/S is Christian F. Rovsing. The other members of the Board of Directors are Claus Jepsen and Lasse Lindblad.

The Managing director of AntibodyShop A/S is Lasse Lindblad, who is also responsible for the entire management of Immunolex Holding ApS and Immunolex Therapeutics ApS.

The purchase price of AntibodyShop A/S – share issue directed to Immunolex Holding ApS

The total share capital of AntibodyShop A/S is being acquired by Realinvest.dk A/S on January 9, 2004 at a purchase price of DKK 35,500,000. This sum is paid to Immunolex Holding ApS in the form of a direct share issue of 11,093,750 new shares in Realinvest.dk A/S of nominal value DKK 3.00 per share, at an issue price of DKK 3.20 per share. The issue price per share has been set at DKK 3.20 in the context of the latest trading rate of DKK 3.00 for shares in Realinvest.dk A/S on the Copenhagen Stock Exchange on December 5, 2003.

The issue price per share has been fixed from a valuation report drawn up on January 7, 2004, according to Danish Company Law, §33, section 1, c.f. also §6a and §6b, by Torben Juncker, RSMplus, Chartered Accountant of Adelgade 15, Copenhagen K. In his valuation of AntibodyShop A/S, chartered accountant Torben Juncker has taken into account the historical financial results of the Company, including the audited annual accounts for 2002, together with a review of the interim accounts for the period January 1 to November 30, 2003. In addition, the plans, budgets and prognoses presented to the end of 2014 have been examined. On this basis AntibodyShop A/S has been valued at at least DKK 35,500,000 after loans carrying interest have been subtracted.

The purchase price represents an excess of DKK 30.984.000 over the net capital in AntibodyShop A/S as recorded in the most recent audited annual accounts.

The valuation report is attached as an appendix to the present statement.

Further directed share issues

In addition to the direct share issue to Immunolex Holding ApS, the Board of Directors of Realinvest.dk A/S has decided to increase the B-share capital by a minimum of DKK 4687,500 nominal value and a maximum of DKK 23,437,500 nominal value, without subscription rights for existing shareholders, corresponding to a cash yield of a minimum of DKK 5,000,000 and a maximum of DKK 25,000,000. The issue price will be DKK 3.20 per share of nominal value DKK 3.00 each. Binding undertakings to purchase B-shares of this directed issue in the form cash payments to a total of DKK 5,000,000 have been received. It is expected that this total cash investment will increase, as the Company is currently negotiating with several potential investors.

Finally, it will be proposed at the next general meeting of shareholders to convert debts totaling DKK 11,519,720 to B-shares at an issue price of DKK 3.20 per share of nominal value DKK 3.00 per share, corresponding to an increase in the nominal share capital of DKK 10,799,738.

In connection with Realinvest.dk A/S's acquisition of the total share capital of AntibodyShop A/S, the directors of the two companies have jointly evaluated the total working capital and financial

requirements of AntibodyShop A/S. On the basis of this evaluation, the expected yield of the directed "cash" share issue in Realinvest.dk A/S will be partly used to increase the capitalization of AntibodyShop A/S by means of a cash injection in the order of magnitude DKK 12,500,000 within the 3 months following the acquisition of the share capital of AntibodyShop A/S. The increased capitalization of AntibodyShop A/S is intended to ensure the availability of the necessary liquid capital for financing existing research and development projects and to intensify marketing activities, including a widening of the Company's international distribution network. The interest-bearing liabilities of AntibodyShop A/S will also be reduced.

It is the opinion of the directors of the two companies that the successful implementation of the above-mentioned capital injection into AntibodyShop A/S, together with AntibodyShop A/S's existing working capital and business base, will be sufficient to finance its capital requirements until AntibodyShop A/S becomes self-financing.

Realinvest.dk A/S depends on a positive result from the directed share issue, entailing the procurement of a cash yield. If it should prove impossible to raise new capital in Realinvest.dk A/S over and above the share-purchase undertakings already received, the Company will within relatively few months be dependent on access to alternative sources of finance or effecting a new share issue. If the present share issue is fully subscribed, the Company's liquid reserves will be sufficient both to carry out the planned capital injection into AntibodyShop A/S and to maintain a suitable capital reserve to be used for possible future small-scale acquisitions.

Share capital and shareholders in Realinvest.dk A/S

Realinvest.dk A/S currently has a nominal share capital of DKK 894,036, consisting of 20,000 A shares of nominal value DKK 3.00 per share, each share carrying 10 votes, and 278,012 B shares of nominal value DKK 3.00 per share, each share carrying 1 vote. Realinvest.dk A/S has a total of 360 registered named shareholders, together accounting for 71.36% of the share capital.

If the extraordinary general meeting should decide to convert liabilities into B-share capital, this conversion will be distributed as follows:

- Immunolex Holding ApS liability of DKK 9,481,720, corresponding to 2,963,038 B shares of nominal value DKK 3.00 per share
- Salt ApS liability of DKK 2,038,000, corresponding to 636,875 B shares of nominal value DKK 3.00 per share

Prior to the directed "cash" share issue by Realinvest.dk A/S, binding undertakings to purchase shares have been received from the following:

- CRE ApS to the amount of DKK 3,450,000 in cash
- DKA-Consult ApS to the amount of DKK 1,550,000 in cash

The Table below shows the current distribution of shares between shareholders in Realinvest.dk A/S and corresponding anticipated distributions when the following transactions have been completed: after the direct share issue to Immunolex Holding ApS in payment of the acquisition of the total share capital of AntibodyShop A/S; after the conversion of liability into B-share capital; and after minimum and maximum subscriptions of new B shares in Realinvest.dk A/S under the planned directed share issue.

Shareholder	Realinvest.dk A/S no. of shares			After acquisition of AntibodyShop A/S no. of shares			After conversion of liabilities no. of shares			Share issue DKK 5,000,000 no. of shares			Share issue DKK 25,000,000 no. of shares		
	A	B		A	B		A	B		A	B		A	B	
Salt ApS	4,000	49,647	18.00%	4,000	49,647	0.47%	4,000	686,522	4.61%	4,000	686,522	4.17%	4,000	686,522	3.03%
Bisgaard-Frantzen		44,021	14.77%		44,021	0.39%		44,021	0.29%		44,021	0.27%		44,021	0.19%
Troels Troelsen		8,840	2.97%		8,840	0.08%		8,840	0.06%		8,840	0.05%		8,840	0.04%
Others	16,000	175,504	64.26%	16,000	175,504	1.68%	16,000	175,504	1.28%	16,000	175,504	1.16%	16,000	175,504	0.84%
Imm. Holding ApS					11,093,750	97.38%		14,056,788	93.76%		14,056,788	84.91%		14,056,788	61.64%
CRE ApS											1,078,125	6.51%		1,078,125	4.73%
DKA-Consult ApS											484,375	2.93%		484,375	2.12%
Others														6,250,000	27.41%
Total	20,000	278,012	100.0%	20,000	11,371,762	100.0%	20,000	14,971,675	100.0%	20,000	16,534,175	100.0%	20,000	22,784,175	100.0%

Troels Troelsen is Chairman of the Board of Directors and majority shareholder in Salt ApS.

New management of Realinvest.dk A/S

In connection with Realinvest.dk A/S's acquisition of the total share capital of AntibodyShop A/S, the Board of Directors of Realinvest.dk A/S has today appointed Lasse Lindblad managing director of Realinvest.dk A/S. Lasse Lindblad has hitherto been responsible for daily operations as managing director of AntibodyShop A/S. At the same time, the previous managing director of Realinvest.dk A/S, Bjarke Dons, has resigned. Lasse Lindblad will henceforth constitute the sole management of Realinvest.dk A/S.

Extraordinary general meeting of shareholders – call to be published January 15, 2004

An extraordinary general meeting of shareholders in Realinvest.dk A/S is called for January 23, 2004, at 9.00 a.m., to be held at Stadionvej 43, DK-5200 Odense V, with the following agenda:

1. Board of Directors' presentation of a) acquisition of the total share capital of AntibodyShop A/S, b) appointment of new management, and c) increasing the Company's B-share capital by a minimum nominal sum of DKK 4,687,500 and a maximum nominal sum of DKK 23,437,500 by means of a directed issue of shares without subscription rights for existing shareholders.
2. Proposal to authorize the Board of Directors to buy back the Company's A shares and B shares, such that individual holdings may constitute up to 10 percent of the Company's share capital
3. Proposal to the general meeting to increase the Company's share capital by converting liabilities of Salt ApS og Immunolex Holding ApS amounting to DKK 11,519,720 into B shares.
4. Proposal to change the Company's articles.

The Board of Directors propose the following changes:

- a. Change of the Company name and secondary names, with the possible extinction of secondary names (several new names are being sought)
 - b. Change of the Company's domicile to the municipality of Gentofte
 - c. Change of the Company's stated purpose / amplification of its stated purpose.
 - d. Amendments to the articles in consequence of new legislation on the presentation of annual accounts.
5. Election of a new Board of Directors.
 6. Proposal on the choice of accountant.

7. Any other business.

Expected financial result

After the acquisition of AntibodyShop A/S, Realinvest.dk A/S expects a negative net income before tax of DKK 0.4 million for the whole accounting year 2003/2004.

This result is affected by costs connected with the acquisition of AntibodyShop A/S and the planned directed share issue.

In the period from its acquisition to May 31, 2004, AntibodyShop A/S expects a turnover of DKK 3.8 million and a positive net income before tax of DKK 0.5 million.

For the accounting year 2004/2005, Realinvest.dk A/S expects a turnover of DKK 10.4 million and a positive net income before interest of DKK 2.0 million.

Realinvest.dk A/S has earlier today published the Company's half-year report.

The future

Realinvest.dk A/S's future strategy will be to undertake successive acquisitions of complementary technology, know-how or other biotechnology companies in the diagnostic field, and in this way strengthen its technology platform and organic growth. This strategy can be expanded if obvious acquisition opportunities arise that open the way to developing therapeutic products that complement the diagnostic business area, e.g. by coupling the sale of diagnostic applications to the sale of products designed to treat the diseases in question. This can be advantageous for product development, registration, pricing and market exclusivity for the two types of product.

The basis for this strategy is that the biotechnology industry in Denmark, and especially in the Øresund region, has never been stronger than at present, and is estimated to be among the strongest in Europe. It is therefore the Board's opinion that many current circumstances support generally good growth prospects for Danish biotechnology. The biotechnology industry in the Øresund region has many interesting and innovative technologies at its disposal, particularly in the area of immunology. It is therefore expected that possible future acquisitions could result in considerable synergic effects.

If possible future acquisitions and the consequent financial requirements for technology and product development should exceed the liquid reserves of Realinvest.dk A/S, the Board is prepared to effect further share issues to raise the necessary capital.

Any enquiries arising from this release should be addressed to the undersigned.

Troels Troelsen
Chairman of the Board of Directors

Tel. (+45) 40 74 71 74
e-mail: troelsen@cbs.dk

Lasse Lindblad
Managing Director

Tel. (+45) 43 62 63 32
e-mail: ll@antibodyshop.com